$21.36
-0.04[-0.19%]
At close: Apr 25
$21.36
0[0.00%]
PreMarket: 5:13PM EDT
Fusion Pharmaceuticals
(NASDAQ:FUSN)Fusion Pharmaceuticals Stock (NASDAQ:FUSN), Analyst Ratings, Price Targets, Predictions
Fusion Pharmaceuticals Inc has a consensus price target of $12.44, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, RBC Capital, and Wedbush on April 16, 2024, March 21, 2024, and March 21, 2024. With an average price target of $15 between TD Cowen, RBC Capital, and Wedbush, there's an implied -29.78% downside for Fusion Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
RBC Capital
Wedbush
Raymond James
B. Riley Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Fusion Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | TD Cowen | Tara Bancroft | — | Downgrade | Buy → Hold | Get Alert |
| 03/21/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | RBC Capital | Gregory Renza | → $21 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/21/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | 12.36% | Wedbush | David Nierengarten | → $24 | Reiterates | Neutral → Neutral | Get Alert |
| 03/20/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | RBC Capital | Gregory Renza | $16 → $21 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/20/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | Raymond James | Rahul Sarugaser | — | Downgrade | Strong Buy → Market Perform | Get Alert |
| 03/20/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | 7.68% | B. Riley Securities | Yuan Zhi | $13 → $23 | Downgrade | Buy → Neutral | Get Alert |
| 03/20/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | Truist Securities | Nicole Germino | $11 → $21 | Downgrade | Buy → Hold | Get Alert |
| 03/20/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | JonesTrading | Justin Walsh | — | Downgrade | Buy → Hold | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | Truist Securities | Nicole Germino | $11 → $21 | Downgrade | Buy → Hold | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | William Blair | Andy Hsieh | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | Brookline Capital | Kemp Dolliver | — | Downgrade | Buy → Hold | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | — | Raymond James | Rahul Sarugaser | — | Downgrade | Strong Buy → Market Perform | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | Jefferies | Andrew Tsai | $10 → $21 | Downgrade | Buy → Hold | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | 12.36% | Wedbush | David Nierengarten | → $24 | Downgrade | Outperform → Neutral | Get Alert |
| 03/19/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -1.69% | Leerink Partners | Faisal Khurshid | $17 → $21 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/04/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -25.09% | RBC Capital | Gregory Renza | $12 → $16 | Maintains | Outperform | Get Alert |
| 01/26/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -39.14% | Wedbush | David Nierengarten | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 01/05/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -29.78% | Oppenheimer | Jeff Jones | $13 → $15 | Maintains | Outperform | Get Alert |
| 01/05/2024 | FUSN | Buy Now | Fusion Pharmaceuticals | $21.36 | -25.09% | Raymond James | Rahul Sarugaser | $15 → $16 | Maintains | Strong Buy | Get Alert |
FAQ
What is the target price for Fusion Pharmaceuticals (FUSN)?
The latest price target for Fusion Pharmaceuticals (NASDAQ: FUSN) was reported by TD Cowen on April 16, 2024. The analyst firm set a price target for $0.00 expecting FUSN to fall to within 12 months (a possible -100.00% downside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Fusion Pharmaceuticals (FUSN)?
The latest analyst rating for Fusion Pharmaceuticals (NASDAQ: FUSN) was provided by TD Cowen, and Fusion Pharmaceuticals downgraded their hold rating.
When was the last upgrade for Fusion Pharmaceuticals (FUSN)?
The last upgrade for Fusion Pharmaceuticals Inc happened on December 27, 2023 when Raymond James raised their price target to $15. Raymond James previously had an outperform for Fusion Pharmaceuticals Inc.
When was the last downgrade for Fusion Pharmaceuticals (FUSN)?
The last downgrade for Fusion Pharmaceuticals Inc happened on April 16, 2024 when TD Cowen changed their price target from N/A to N/A for Fusion Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Fusion Pharmaceuticals (FUSN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fusion Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fusion Pharmaceuticals was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Fusion Pharmaceuticals (FUSN) correct?
While ratings are subjective and will change, the latest Fusion Pharmaceuticals (FUSN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Fusion Pharmaceuticals (FUSN) is trading at is $21.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.